Ocugen, Inc. priced an underwritten offering of 15 million shares of its common stock at $1.50 per share, generating gross proceeds of $22.5 million before fees and expenses. The offering, led by RTW Investments and managed by Oppenheimer & Co., is expected to close on or about January 22 2026.
The company will use the net proceeds for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. The move is intended to extend Ocugen’s limited cash balance and support ongoing clinical development of its gene‑therapy pipeline.
Ocugen’s cash position has been under pressure, with the balance falling from $58.8 million at the end of December 2024 to $27.3 million at the end of June 2025. The company’s financial profile is further strained by negative operating and net margins, a high debt‑to‑equity ratio, and an Altman Z‑Score of –6.66, placing it in the distress zone. Historically, Ocugen has raised equity multiple times to extend its runway, most recently a $20 million direct offering in August 2025 and a $35 million equity raise in August 2024.
The capital raise is a critical step for Ocugen to fund its gene‑therapy pipeline, which includes OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy, and OCU410ST for Stargardt disease. Management has indicated that the proceeds will help sustain the company’s clinical program and support the filing of three biologics license applications within the next three years.
Investors reacted negatively to the announcement, citing the dilutive nature of the offering and the fact that the price of $1.50 per share was below the prevailing market price. The reaction reflects broader concerns about Ocugen’s ongoing need for external financing and the impact of dilution on shareholder value.
The offering represents a material financing event that is new, has sufficient detail, and is not a duplicate of prior coverage. It is therefore appropriate for publication.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.